Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Rosenberg

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Medical Oncology (Northwood, London, England)|November 5, 2014
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS studyKlaus Pietzner, Ignace Vergote, Armando Santoro, et al.
BMC Cancer|February 7, 2014
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)Kristina Lindemann, Susanne Malander, Rene D Christensen, et al.
Gynecologic Oncology|November 8, 2016
Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG)Pernilla Dahm-Kähler, Christer Borgfeldt, Erik Holmberg, et al.
Acta Oncologica (Stockholm, Sweden)|May 30, 2013
Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcomeAnne von Heideman, Bengt Tholander, Birgitta Grundmark, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 7, 2006
The in vivo contributions of TASK-1-containing channels to the actions of inhalation anesthetics, the alpha(2) adrenergic sedative dexmedetomidine, and cannabinoid agonistsAnni-Maija Linden, M Isabel Aller, Elli Leppä, et al.
Acta Obstetricia Et Gynecologica Scandinavica|May 28, 2022
Long-term incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group (SweGCG) studyAngelique Flöter Rådestad, Pernilla Dahm-Kähler, Erik Holmberg, et al.
Acta Oncologica (Stockholm, Sweden)|November 14, 2017
Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) studyElisabet Hjerpe, Christian Staf, Pernilla Dahm-Kähler, et al.
Acta Oncologica (Stockholm, Sweden)|August 23, 2017
Data quality in the Swedish Quality Register of Gynecologic Cancer - a Swedish Gynecologic Cancer Group (SweGCG) studyPer Rosenberg, Preben Kjølhede, Christian Staf, et al.
Acta Oncologica (Stockholm, Sweden)|November 5, 2021
The wait time to primary surgery in endometrial cancer - impact on survival and predictive factors: a population-based SweGCG studyJanusz Marcickiewicz, Elisabeth Åvall-Lundqvist, Erik Carl Viktor Holmberg, et al.
Gynecologic Oncology|September 29, 2020
Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG studyKristina Hellman, Erik Holmberg, Maria Bjurberg, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Medical Oncology (Northwood, London, England)|November 5, 2014
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS studyKlaus Pietzner, Ignace Vergote, Armando Santoro, et al.
BMC Cancer|February 7, 2014
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)Kristina Lindemann, Susanne Malander, Rene D Christensen, et al.
Gynecologic Oncology|November 8, 2016
Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG)Pernilla Dahm-Kähler, Christer Borgfeldt, Erik Holmberg, et al.
Acta Oncologica (Stockholm, Sweden)|May 30, 2013
Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcomeAnne von Heideman, Bengt Tholander, Birgitta Grundmark, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 7, 2006
The in vivo contributions of TASK-1-containing channels to the actions of inhalation anesthetics, the alpha(2) adrenergic sedative dexmedetomidine, and cannabinoid agonistsAnni-Maija Linden, M Isabel Aller, Elli Leppä, et al.
Acta Obstetricia Et Gynecologica Scandinavica|May 28, 2022
Long-term incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group (SweGCG) studyAngelique Flöter Rådestad, Pernilla Dahm-Kähler, Erik Holmberg, et al.
Acta Oncologica (Stockholm, Sweden)|November 14, 2017
Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) studyElisabet Hjerpe, Christian Staf, Pernilla Dahm-Kähler, et al.
Acta Oncologica (Stockholm, Sweden)|August 23, 2017
Data quality in the Swedish Quality Register of Gynecologic Cancer - a Swedish Gynecologic Cancer Group (SweGCG) studyPer Rosenberg, Preben Kjølhede, Christian Staf, et al.
Acta Oncologica (Stockholm, Sweden)|November 5, 2021
The wait time to primary surgery in endometrial cancer - impact on survival and predictive factors: a population-based SweGCG studyJanusz Marcickiewicz, Elisabeth Åvall-Lundqvist, Erik Carl Viktor Holmberg, et al.
Gynecologic Oncology|September 29, 2020
Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG studyKristina Hellman, Erik Holmberg, Maria Bjurberg, et al.
Pageof 5